Kane Biotech Receives Health Canada Approval for revyve Antimicrobial Wound Gel Spray, Presents Clinical Data at Wound Healing Conference
Key Insights
Kane Biotech received Health Canada approval for its revyve Antimicrobial Wound Gel Spray (search), providing Canadian clinicians with a new tool for managing burns (search), large surface area wounds and ulcers (search).
The company presented new clinical data at the Innovations in Wound Healing Annual Meeting, demonstrating improved healing trajectories in chronic wounds (search) and efficacy across different wound types.
Clinical case studies showed the versatility of Kane's wound gel platform across multiple sites and standards of care, including effectiveness in highly exudative wounds.
Kane Biotech Inc. (search) has achieved a significant regulatory milestone with Health Canada's approval of its revyve Antimicrobial Wound Gel Spray (search), expanding access to the company's biofilm-disrupting wound care technology for Canadian healthcare providers. The approval comes as the company presented compelling new clinical data at the Innovations in Wound Healing Annual Meeting in Key West, Florida.
Regulatory Milestone Expands Canadian Market Access
Health Canada's approval of the revyve Antimicrobial Wound Gel Spray (search) represents another regulatory achievement for Kane Biotech, following the product's previous FDA 510(k) clearance. The spray formulation is designed to support clinicians in managing complex wounds by helping to reduce microbial burden and promote a healthier wound environment.
"Health Canada's approval of the revyve Antimicrobial Wound Gel Spray (search) is another step forward in our mission to improve outcomes for patients with chronic and hard-to-heal wounds," said Dr. Robert B. Huizinga, Interim CEO of Kane Biotech. "This approval validates the strength of our clinical data and provides Canadian healthcare providers with a new tool to address the burden of wound infections (search)."
The approval provides Canadian clinicians and patients with access to a new wound care option specifically for managing burns (search), large surface area wounds and ulcers (search). Kane Biotech plans to work closely with healthcare partners and distributors to ensure appropriate access and education around the use of the spray formulation.
Clinical Data Demonstrates Versatility Across Wound Types
At the Innovations in Wound Healing Annual Meeting, Kane Biotech shared comprehensive case study data from across its wound care portfolio, highlighting the technology's effectiveness in addressing complex and high-burden health conditions. The presentations demonstrated several key clinical outcomes:
The company's advanced wound gel platform showed improved healing trajectories in chronic wounds (search), with versatility demonstrated across multiple sites and standards of care. The data revealed efficacy over different application frequencies, dressing types, and wound classifications, including highly exudative wounds that present particular treatment challenges.
Breakthrough in Radiation-Compromised Tissue
Particularly noteworthy were new findings in a chronic radiation-induced Achilles ulcer (search) case, showing how Kane's wound gel technology supports healing in radiation-compromised tissue where conventional therapies often fail. This represents a significant advancement for patients dealing with radiation-related wound complications, a notoriously difficult-to-treat condition.
Progress in Hidradenitis Suppurativa Treatment
The company also presented data in Hidradenitis Suppurativa (search) (HS), illustrating revyve's potential to reduce infection burden and improve outcomes in this debilitating condition. HS represents a significant unmet medical need, and the data suggests Kane's biofilm-disrupting technology may offer new therapeutic options for affected patients.
Market Adoption and Clinical Integration
The presentations included market adoption insights, reflecting how Kane's innovations are being integrated into care pathways and delivering measurable value to health systems. This real-world evidence supports the clinical utility of the revyve platform beyond controlled study environments.
"These presentations highlight Kane Biotech's dedication to advancing wound care innovation across a spectrum of challenging conditions," Dr. Huizinga noted. "By sharing our latest data at IWH, we continue to strengthen our role as a trusted partner in improving patient outcomes and supporting health systems with effective, science-driven solutions."
Expanding Product Portfolio
Kane Biotech continues to advance its wound care portfolio beyond the newly approved spray formulation. The company recently submitted its revyve Antimicrobial Wound and Skin Cleanser (search) to the FDA as the third product in its revyve product line, demonstrating ongoing commitment to expanding treatment options.
The revyve platform addresses biofilms (search), which are recognized as one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant healthcare costs. The technology targets both biofilms and wound bacteria (search), offering a dual mechanism of action for complex wound management.
Both the revyve Antimicrobial Wound Gel (search) and revyve Antimicrobial Wound Gel Spray (search) have received FDA 510(k) clearance, while the gel formulation also holds Health Canada approval. This regulatory foundation positions Kane Biotech to serve both U.S. and Canadian markets with its innovative wound care solutions.